Nerai Bio

Nerai Bio is a Swiss biotechnology company that develops high-precision genome editing therapies for rare inherited diseases. The company utilizes its proprietary MORPHEME platform, which integrates large-scale automated directed evolution, high-throughput cell-based functional screening, and machine learning. This technology allows for the design of bespoke, CRISPR-based gene editors with enhanced specificity, safety, and efficiency, overcoming the targeting limitations associated with standard CRISPR-Cas9 proteins. By fusing artificial intelligence with programmable biology, Nerai creates editors capable of targeting mutations that were previously considered inaccessible, focusing on initial therapeutic programs for rare liver and eye disorders.

Nerai's approach aims to provide curative, one-time genetic therapies that address significant unmet medical needs in patients currently managed with inadequate lifelong supportive care. By improving the precision and safety of gene editing tools, the company strives to expand the range of treatable genetic conditions and redefine the landscape of genetic medicine. Supported by competitive grants and research fellowships from institutions such as Innosuisse, the University of Zurich, and Venture Kick, Nerai is actively advancing its lead candidates into preclinical validation and seeking strategic partnerships with biopharmaceutical leaders to accelerate the deployment of its transformative therapies.